feedback

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit
Released: November 13, 2017
Expires: November 12, 2018
30 minutes to complete

***This activity was recorded on September 21, 2017. Abemaciclib was subsequently approved by the FDA for use in the treatment of HR+/HER2- breast cancer on September 28, 2017.

Provider

This activity is provided by Imedex, LLC.

Overview

The approvals of palbociclib and ribociclib, the first cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, provided advanced or metastatic hormone-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer patients with promising new treatment options. With a third CDK4/6 inhibitor, abemaciclib, approved in late September 2017, this class of therapy has become the new standard of care for HR+/HER2- breast cancer, which comprises the majority (approximately 75%) of all breast cancer cases. This interactive activity features expert faculty discussing practical aspects of using this class of agents as second-line therapy in HR+/HER2- advanced or metastatic breast cancer.

Learning Objectives

Upon successful completion of this educational activity, participants should be better able to:

  • Describe the mechanisms of CDK4/6 inhibition and its relevance to HR+/HER2- breast cancer
  • Assess the safety and toxicity profiles of each approved and the emerging CDK4/6 inhibitor agent and the resulting needs for different types of monitoring
  • Devise a strategy to encourage patient adherence to a CDK4/6 regimen

Target Audience

This educational activity is designed to meet the educational needs of US-based community medical oncologists and other healthcare professionals involved and/or interested in the management of patients with breast cancer.

Chair

Harold J. Burstein, MD, PhD
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts


Faculty

Joyce O’Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research,
Baylor University Medical Center
Texas Oncology
Co-Chair, Breast Cancer Research Program,
The US Oncology Network
The Woodlands, Texas


Continuing Education

Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex, LLC designates this internet-based enduring educational activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credits™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.5 hour of Category 1 credit for completing this program.

In order to receive credit, participants must successfully complete the post-test and complete the online evaluation form. You will receive an online CME statement of credit to print for your records.

Support

Supported by an educational grant from: Novartis Pharmaceuticals Corporation.

Disclosure of Financial Relationships

As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), Imedex, LLC must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Faculty are instructed to provide a balanced view of therapeutic options by utilizing generic names to ensure impartiality.

Faculty Disclosures

All faculty participating in an Imedex activity are required to disclose relevant financial relationships that may be considered to be related to the subject matter of the educational activity. Disclosure of these commitments and/or relationships is included in these course materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

The following indicates the faculty disclosure declaration information and the nature of those commercial relationships.

1=grant/research support 2=consultant 3=speaker’s bureau 4=stock shareholder 5=other support
Joyce O'Shaughnessy, MD: AstraZeneca(2), Celegene(2), Lilly(2), Novartis Pharmaceuticals Corporation(2,3), Pfizer(2)

The following speakers do not report any affiliation:
Harold J. Burstein, MD, PhD                 

All materials are included with the permission of the authors.

Imedex Staff Disclosures

All Imedex staff members who are in a position to control content of this activity have no financial relationships with any commercial interests, except for the following individuals:

Chris Bolwell owns shares of stock of GlaxoSmithKline.

Unapproved Uses

This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the US Food and Drug Administration (FDA) and/or other national regulatory agencies in the United States and other countries. Participants in the United States are encouraged to consult the FDA-approved product labeling for any drug or device mentioned in this program before use. Participants from other countries should consult with their respective regulatory authorities.

The opinions expressed in this webcast are the opinions of the authors and do not necessarily reflect the opinions of Imedex.

Disclaimer

The material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.

About Imedex

Imedex is a brand and assumed name used by Imedex, LLC (hereby referred to as Imedex). Imedex is solely responsible for this agenda’s content. Although Imedex attempts to ensure that the information in our program is accurate and timely, matters and opinions discussed and/or presented with respect to clinical matters are those of the discussion participants only, and not necessarily those of Imedex. Moreover, although Imedex attempts to identify and integrate the most qualified medical professionals in our program, TO THE FULLEST EXTENT PERMITTED BY LAW, IMEDEX EXPRESSLY DISCLAIM ALL WARRANTIES, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT OF THIRD PARTIES’ RIGHTS, AND FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THE CONTENT PRESENTED. IMEDEX FURTHER MAKES NO REPRESENTATIONS OR WARRANTIES ABOUT THE ACCURACY, RELIABILITY, COMPLETENESS OR TIMELINESS OF THE CONTENT OR ANY MATERIAL PRESENTED.

© 2017 Imedex, LLC. All rights reserved. Reproduction in whole or part is prohibited without prior written consent from Imedex and contributing faculty.

For comments or inquiries, please contact:
Imedex, LLC
11675 Rainwater Drive, Suite 600
Alpharetta, GA 30009, USA
Fax: +1(770) 751-7334
Email: elearning@imedex.com

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Start Activity

Select your specialty

You must select a specialty

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.